EZH2 and diffuse large B-cell lymphoma: GSK126 treatment of SUDHL4 and Karpas-422 cells leads to a significant decrease in H3K27me3 following 48h treatment of cells with this EZH2 inhibitor (Figure 4), but viability or cell cycle progression of these chemoresistant DLBCL cells is not compromised at this time point or even after 72h post-incubation with GSK126 (Figure 3).